Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 11/20 | 0.39 |
| ▸ | CDK2 | P24941 | 11/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.39 |
| ▸ | AURKA | O14965 | 8/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26372096 | 0.86 | CREBBP (0.36) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17518297 | 0.86 | CREBBP (0.43) | EP300CREBBPMAPK1 | |
| SCHEMBL26372099 | 0.84 | CREBBP (0.37) | KIF11EP300CREBBPMAPK1 | |
| SCHEMBL16123821 | 0.81 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL1704668 | 0.81 | CCNA2 (0.42) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17234814 | 0.80 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17232775 | 0.77 | CCNA2 (0.41) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17232797 | 0.77 | AURKA (0.39) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17232799 | 0.77 | CREBBP (0.47) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17232800 | 0.77 | RBP4 (0.44) | CCNA2CDK2CCNA1AURKACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-05 | — | — | US | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | QDPR, DPYD, DHPS | CCNA2 2723/4885CDK2 1427/4885CCNA1 3516/4885 |
| US-20230312585-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | CCNA2 1032/4885CDK2 753/4885CCNA1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.